Press Releases

Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference

Sep 30, 2021

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

Sep 08, 2021

Turning Point Therapeutics to Participate In Upcoming Investor Conferences

Sep 01, 2021

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Aug 16, 2021

Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib

Aug 11, 2021

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Aug 09, 2021

Turning Point Therapeutics to Host Second Quarter 2021 Conference Call

Jul 28, 2021

Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer

Jun 29, 2021

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Jun 17, 2021

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference

Jun 01, 2021